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Abstract
Background and Objectives
Sudden cardiac death (SCD) is a severe burden of modern medicine. Aldosterone antago-
nist is publicized as effective in reducing mortality in patients with heart failure (HF) or post
myocardial infarction (MI). Our study aimed to assess the efficacy of AAs on mortality
including SCD, hospitalization admission and several common adverse effects.
Methods
We searched Embase, PubMed, Web of Science, Cochrane library and clinicaltrial.gov for
randomized controlled trials (RCTs) assigning AAs in patients with HF or post MI through
May 2015. The comparator included standard medication or placebo, or both. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were fol-
lowed. Event rates were compared using a random effects model. Prospective RCTs of
AAs with durations of at least 8 weeks were selected if they included at least one of the
following outcomes: SCD, all-cause/cardiovascular mortality, all-cause/cardiovascular
hospitalization and common side effects (hyperkalemia, renal function degradation and
gynecomastia).
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Results
Data from 19,333 patients enrolled in 25 trials were included. In patients with HF, this treat-
ment significantly reduced the risk of SCD by 19% (RR 0.81; 95%CI, 0.67–0.98; p = 0.03);
all-cause mortality by 19% (RR 0.81; 95% CI, 0.74–0.88, p<0.00001) and cardiovascular
death by 21% (RR 0.79; 95%CI, 0.70–0.89, p<0.00001). In patients with post-MI, the match-
ing reduced risks were 20% (RR 0.80; 95% CI, 0.66–0.98; p = 0.03), 15% (RR 0.85; 95%CI,
0.76–0.95, p = 0.003) and 17% (RR 0.83; 95% CI, 0.74–0.94, p = 0.003), respectively. Con-
cerning both subgroups, the relative risks respectively decreased by 19% (RR 0.81; 95% CI,
0.71–0.92; p = 0.002) for SCD, 18% (RR 0.82; 95% CI, 0.77–0.88, p < 0.0001) for all-cause
mortality and 20% (RR 0.80; 95% CI, 0.74–0.87, p < 0.0001) for cardiovascular mortality in
patients treated with AAs. As well, hospitalizations were significantly reduced, while common
adverse effects were significantly increased.
Conclusion
Aldosterone antagonists appear to be effective in reducing SCD and other mortality events,
compared with placebo or standard medication in patients with HF and/or after a MI.
Introduction
Sudden cardiac death (SCD) is defined as unexpected natural death from a cardiac cause within
a short time period, generally within one hour from the onset of symptoms, in a person without
any prior condition that would appear fatal [1][2]. Patients with previous myocardial infarc-
tions (MI) or cardiac arrest or congestive heart failure (HF) were much more likely to have
inducible arrhythmias, considered as a common cause of SCD [3].
The renin-angiotensin aldosterone hormone system’s (RAAS) main function is to maintain
the homeostasis of arterial pressure and of extracellular fluids [4]. Dysregulation of this system
leads to cardiovascular (CV) disorders including left ventricular remodeling, vasoconstriction/
hypertension, and ventricular hypertrophy which may eventually result in SCD [5]. The hor-
monal cascade is initially induced by a decrease in blood volume which enhances renin secre-
tion into the blood stream, resulting in the production of angiotensin II that is responsible for
blood pressure increase via blood vessel constriction and the stimulation of the aldosterone
hormone production. Aldosterone in its turn promotes the reabsorption of sodium and water,
also leading to an increase in blood pressure [4].
Aldosterone antagonist (AA) inhibits sodium reabsorption and slightly increases water
excretion [6]. This group of drugs, including spironolactone, eplerenone, and canrenone
among others, is often used in managing chronic and congestive HF [7][8]. Officially, AA treat-
ment is recommended in clinical practice at a low-dose in all patients with a left ventricular
ejection fraction (LVEF)< 35% and severe symptomatic HF, i.e. currently New York Heath
Association (NYHA) functional class III or IV, in absence of hyperkalemia and significant
renal dysfunction, unless contraindicated or not tolerated. It is also recommended in patients
suffering acute myocardial infarction (AMI) with LVEF 40% and developing HF symptoms
or having a history of diabetes mellitus, unless contraindicated [9][10].
The benefits of AA in reducing the negative effects of aldosterone hence decreasing death
and hospitalization in HF or AMI patients have been demonstrated in four major trials, includ-
ing RALES (Randomized Aldactone Evaluation Study) [11], EMPHASIS-HF (Eplerenone in
Aldosterone Antagonists and Sudden Death in High Risk Patients
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Mild Patients Hospitalization and Survival Study in Heart Failure) [12], EPHESUS (Eplere-
none Post-AMI Heart Failure Efficacy and Survival Study) [13] and most currently TOPCAT
(Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)
[14].
Our study aimed to assess the efficacy of AA on SCD, hospitalization admission and several
common adverse events in patients with HF or post MI.
Methods
Inclusion and exclusion criteria
We included randomized controlled trials (RCTs) comparing spironolactone or eplerenone or
canrenoate potassium to placebo or standard treatment. Studies were included if they recruited
patients with left ventricular dysfunction HF (NYHA class I to IV) and/or post AMI with Killip
scores between I and IV and indicated at least one assessment criteria. Our meta-analysis clas-
sified these patients into two corresponding sub-categories: HF and post-MI. The included
studies had to report at least one of the following outcomes: SCD, all-cause/CV mortality, all-
cause/CV hospitalization and common side effects (hyperkalemia, renal function degradation
and gynecomastia).
We excluded studies with a follow-up period< 8 weeks. Trials with inestimable treatment
effect (no event in both arms for all criteria) and small sample size (<40 patients/arm) were
excluded. The lack of double-blind and/or intention-to-treat analysis of AA efficacy was not an
exclusion criterion but was re-examined by sensibility test afterwards.
Search strategy
The research was conducted systematically from Embase, Medline (Pubmed), Cochrane
Library, Web of science and clinicaltrials.gov from 1966 to 31/05/2015 (details of search strat-
egy in S1 App). We searched for studies involving human subjects, clinical trials, RCTs and/or
meta-analyses and/or systematic reviews. No language restriction was applied. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15] were
followed (S2 App).
Study screening and analyzing through titles and abstracts was performed independently by
several investigators in different periods (HHL, MM, CK, TA, FG), according to the pre-speci-
fied selection criteria. Data were extracted independently and compared afterwards. The latest
screening and data extraction (through May 2015) were conducted independently by two
investigators (HHL &MM) with kappa statistics (S3 App). Cochrane bias criteria [16] were
used to evaluate the overall quality of the articles. An included trial was considered as of high
quality if all its risks of bias were low. Disagreements were discussed and decisions were made
through consensus. A third party (FG) was involved when necessary. The following informa-
tion was extracted from the studies: the first author or study name, year of publication, baseline
patient characteristics, intervention and related outcomes. Besides database searching, refer-
ence lists of all included studies, meta-analyses and reviews were manually searched for further
potential trials and/or information validation.
Outcomes assessment
The primary endpoints were SCD, total mortality and CV mortality at the end of the follow-up
duration. Secondary outcomes were hospitalization (from all causes and CV causes) and
adverse reaction events (hyperkalemia, renal function degradation and gynecomastia) by AAs.
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Statistical analysis
Kappa statistic was calculated for agreement ratio between two latest reviewers (HHL &MM)
(S3 App). We extracted aggregate data, number of events and number of patients in each sub-
group from included studies, using fixed-effect and random-effect models to pool the data.
Results were reported as relative risk (RR) at 95% confidence intervals (CI) using the Mantel
and Haenszel method for the fixed-effect model [17] or the DerSimonian and Laird method
for the random-effect model [18]. When similar outcomes were obtained by both methods, we
only reported the random-effect results to cover possible heterogeneity as several pharmaco-
logic drugs and different patients were included.
Heterogeneity across studies was estimated using I2 test [18]. I2 values of 25%, 50%, and
75% correspond to low, moderate, and high levels of heterogeneity [19]. Meta-analysis results
were considered only if the I2 value was below 75%. Potential existence of publication bias was
assessed in both subgroups at each criterion of outcome by funnel plots and verified by the
Egger tests [20] using odds ratio (OR) since firm guidance for RR is not yet available [21]. Sen-
sitivity analysis was carried out for each outcome measure to evaluate the contribution of each
study to the pooled estimate by excluding important trials/ lack of blinding trials/ lack of inten-
tion-to-treat analysis trials at one time and recalculating the combined RR for the remaining
studies. Statistical testing was two-tailed, with statistical significance declared at 5%. All analy-
ses were performed using RevMan (version 5.3) and R (version 3.2.2) softwares.
Results
Search results
Our search through Embase, Medline (Pubmed), Cochrane Library, Web of science, clinical-
trials.gov and other sources (www.clinicaltrialsregister.eu & www.trialdetails.com) returned a
total of 3653 studies. After elimination of duplicates, 3143 studies were retained for evaluation.
Through screening of titles and abstracts, 2644 and 320 irrelevant studies were respectively
excluded, respectively. Following full manuscript review of the remaining 80 studies, 54 addi-
tional ones were excluded: full-text not available (n = 10) (correspondences to authors were
made but we have not received positive responses), study period<8 weeks (n = 8), review,
editorial commentary or study design (n = 8), sub-study (n = 3), not RCT (n = 5), and out-
comes of interest not available (n = 21). Finally, 25 studies satisfying all selection criteria were
included in this meta-analysis (Fig 1). The kappa statistic indicated a subtidal agreement good
at 0.75 (IC 95% CI, 0.49–1.02; p = 0.0005) (S3 App).
The quality of evidence of included studies was relatively high: 100% of low risk for selec-
tion, attrition and reporting biases, 70% of low risk for performance bias and>85% of low risk
for detection bias (S1 Fig).
Study characteristics
In total, 25 RCTs [11],[13–14],[22–32],[33–43] were selected in this meta-analysis, which
enrolled a total of 19333 patients (9750 for AA arm and 9583 for control/placebo arm). The
mean follow-up duration was 12.42 months (1.04 year). All trials were placebo controlled
except three trials [22][23][24] which applied routine treatment. Nine trials [25][26][27][28]
[13][29][30][31][24] assessed the effect of AAs in post-AMI patients with left ventricular dys-
function; while the other trials recruited HF patients. Duration of follow-up varied from 3 to
44 months. Spironolactone was the most commonly used AAs (15 studies), followed by eplere-
none (7 studies) and canrenone (3 studies) (Table 1). The risk of bias of included trials was pre-
sented in S1 Table and S1 Fig.
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Baseline patient characteristics
Most trials included elderly people with mean age ranged from 50–80 years (Table 1). Most of
studies consisted dominantly male participants, except two trials [26][23] where more women
were recruited and the trial of Edelmann et al. [32] which had a relatively equal sex ratio.
All trials were restricted to patients without renal dysfunction (kalemia<5.5 mmol/l and
creatinine< 2.5 mg/dL) (Table 2).
Primary outcomes
Sudden cardiac death. In the 25 included articles, six accounting for 8301 subjects (4132
used AAs and 4169 received placebo/control) reported SCD events in patients with HF. In the
Fig 1. Study flowchart for the selection process of the final included trials.
doi:10.1371/journal.pone.0145958.g001
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Table 1. Main characteristics of included studies.
Studies,
(abbreviation
name), year of
publication
Patients;
duration
(follow-up);
countries
Comparison Study
design,
intention to
treat
analysis
(ITTA)
Number of
randomized
patients
(excluded
during follow-
up)
Mean age
(SD)
Male
sex
(%)
Ischemic
etiology
(%)
Ejection
fraction (%)
Boccanelli et al.
2009 (AREA-in-HF)
[35]
HF; 12 months;
Italy
Canrenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
231(43)/ 236(42) 62.3(9.5)/
62.7(9.5)
82/85 51.1/ 52.1 39.9(8.6)/
39.7(8.6)
Chan et al. 2007
[56]
HF; 12 months;
China
Spironolactone 25
mg/day
+ candesartan vs.
Placebo
+ candesartan
DB; with
ITTA
23(0)/25(0) 61.4(12.3)/
65(0.6)
87/80 47.8/ 64.0 26(2)/28(2)
Cicoira et al. 2002
[22]
HF; 12 months;
Italy
Spironolactone 25
mg (titrated to 50
mg/day) vs. Routine
treatment
Open label,
without ITTA
54(7)/52(6) 62.5(7.9)/
61.7(9.8)
85/88 65/63 33(7)/34(7)
Deswal et al. 2011
(RAAM-PEF) [36]
HF; 6 months;
USA
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
23(2)*/23(0)* 72.2(9.8)*/
68.7(9.1)*
95*/
91*
NR/NR 62.1(5)*/
62.5(7.5)*
Di Pasquale et al.
2005 [25]
MI; 6 months;
Italy
Canrenoate IV 1
mg/h then 25 mg
PO/day + Captopril
vs. Placebo
+ Captopril
DB; without
ITTA
341(33)/ 346(30) 62.6(6)/ 62.8
(5)
71/71 100/100 NR/NR
Edelmann et al.
2013 (Aldo-DHF)
[32]
HFPEF; 12
months;
Germany
&Austria
Spironolactone 25
mg/day vs. Placebo
DB; with
ITTA
213(0)/209(0) 67(8)/67(8) 48/47 NR/NR 67(8)/68(7)
Gao et al. 2007 [57] HF; 6 months;
China
Spironolactone 20
mg/day vs. Placebo
DB, with
ITTA
58(0)/58(0) 55(13)/54(12) 64/66 50/52 42(11)/43
(10)
Kayrak et al. 2010
[26]
AMI; 6 months;
Turkey
Spironolactone 25
mg/day vs. Routine
treatment
Open label,
without ITTA
71(16)/71(16) 55.3(10)*/
57.2(11)*
18*/
26*
100/100 50.5(8.3)*/
49.5(8)*
Mak et al. 2009 [23] DHF; 12 months;
Ireland
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Routine
treatment
Open label,
without ITTA
24(1)/20(3) 80(7.7)/ 79
(7.9)
38/55 NR/NR 63(9.0)/64
(9.6)
Modena et al. 2001
[27]
MI; 12 months;
Italy
Potassium
canrenoate 50 mg/
day vs. Placebo
NR, with
ITTA
24(0)/22(0) 59(10)/62(13) 71/77 100/100 47(6)/46(5)
Montalescot et al.
2014 (REMINDER)
[28]
MI; 10.5 months;
International (11
countries)
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; with
ITTA
506(82)/506(79) 58.5(10.8)/
57.8(11.0)
83/80 100/100 NR/NR
Pitt et al. 2014
(TOPCAT) [14]
HF; 3.3 years;
International (6
countries)
Spironolactone (15
to 45 mg/day) vs.
Placebo
DB; with
ITTA
1722(0)/ 1723(0) 68.7(median)
range 61.0–
76.4/ 68.7
(median)
range 60.7–
75.5
NR/
NR
NR/NR 56(median)
range 51–
61/ 56
(median)
range 51–62
Pitt et al. 2003
(EPHESUS) [13]
LVD after MI; 16
months (range
0–33);
International (37
countries)
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; with
ITTA
3319(0)/ 3313(0) 64(11)/64(12) 72/70 100/100 33(6)/33(6)
(Continued)
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follow-up duration, the SCD rate in HF patients was 4.89% (n = 202/4132) in those treated
with AAs, compared with 6.09% (n = 254/4169) in those treated with placebo/control. In post-
MI patients, SCD was reported only in the EPHESUS trial [13] at the rates of 4.88% (n = 162/
3319) and of 6.07% (n = 201/3313) in groups receiving AAs and placebo, respectively.
Table 1. (Continued)
Studies,
(abbreviation
name), year of
publication
Patients;
duration
(follow-up);
countries
Comparison Study
design,
intention to
treat
analysis
(ITTA)
Number of
randomized
patients
(excluded
during follow-
up)
Mean age
(SD)
Male
sex
(%)
Ischemic
etiology
(%)
Ejection
fraction (%)
Pitt et al. 1999
(RALES) [11]
HF; 24 months;
International (15
countries)
Spironolactone 25
mg (titrated to 50
mg/day) vs. Placebo
DB; with
ITTA
822(0)/841(0) 65(12)/65(12) 73/73 55/54 25.6(6.7)/
25.2(6.8)
Taheri et al. 2012
[37]
CHF; 6 months;
Iran
Spironolactone 25
mg/day vs. Placebo
DB; without
ITTA
9(2)/9(3) 50.7(17.4)/
57.2(13.1)
55/55 NR or 0/
NR or 0
26.6(8.3)/
31.1(10.5)
Taheri et al. 2009
[38]
HF; 6 months;
Iran
Spironolactone 25
mg/day vs. Placebo
DB; without
ITTA
8(3)/8(2) 59.5(6.5)/
56.8(9.3)
63/75 NR or 0/
NR or 0
31.3(8.7)/
33.8(9.2)
The RALES
Investigators [58]
HF; 3 months;
International
Spironolactone 12.5,
25, 50, 75 mg/day (4
groups) vs. Placebo
DB; with
ITTA
174(0)/40(0) 63/61(12) 79/83 NR/NR NR/NR
Udelson et al. 2010
[39]
HF; 9 months;
USA
(multicenter)
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
117(13)/109(20) 63.3(12.2)/
62.0(12.9)
84/84 60/61 26.2(0.6)/
27.0(0.6)
Uzunhasan et al.
2009 [29]
AMI; 6 months;
Turkey
Spironolactone 50
mg/day vs. Placebo
DB; with
ITTA
41(0)/41(0) 52(10)/52(10) 79/71 NR/NR 47/44
Vatankulu et al.
2013 [30]
AMI; 6 months;
Turkey
Spironolactone 12.5
& 25 mg/day (2
groups) vs. Routine
treatment
Open label;
with ITTA
104(0)/56(0) 56/57(11) 84/80 100/100 NR/NR
Vizzardi et al. 2013
[34]
CHF; 44 ± 16
months; Italy
Spironolactone 25
mg (titrated to 100
mg/day) vs. Placebo
SB; without
ITTA
65(5)/65(1) 61(14.7)/ 65
(17.4)
NR/
NR
NR/NR 34.5(6.8)/
37.7(11)
Vizzardi et al. 2010
[59]
HF; 6 months;
Italy
Spironolactone 25
mg (titrated to 100
mg/day) vs. Placebo
SB; with
ITTA
79(0)/79(0) 61(13)/58(13) 84/82 NR/NR 35.2(0.7)/
35.4(1.0)
Weir et al. 2009
[31]
MI; 5.5 months;
UK
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; without
ITTA
50(4)/50(3) 61.0 12.0)*/
56.8(12.0)*
74*/
80*
100/100 35.2(3.9)*/
32.3(4.8)*
Wu et al. 2013 [24] AMI; 12 months;
China
Spironolactone 20
mg/day vs. Routine
treatment
Open label;
without ITTA
308(46)/308(42) 59.8(11.7)*/
59.9(10.3)*
74*/
72*
100/100 NR/NR
Zannad et al. 2011
(EMPHASIS-HF)
[33]
HF; 21 months;
International
Eplerenone 25 mg
(titrated to 50 mg/
day) vs. Placebo
DB; with
ITTA
1364(0)/ 1373(0) 68.7(7.7)/
68.6(7.6)
77/78 70/68 26.2(4.6)/
26.1(4.7)
The results are shown according to the mean (SD), except for additional explanation in exceptional cases. BD: double blind; ITTA: intention to treat
analysis; HF: Heart failure; DHF: Diastolic heart failure; CHF: congestive heart failure; HFPRE: Heart failure with preserved ejection fraction; MI:
Myocardial infarction; LVD: Left Ventricular Dysfunction; IV: Intra-venous; DB: Double blind; SB: Single blind; NR: not reported; AREA-in-HF: Aldosterone
Receptor Antagonists improve outcome in severe Heart Failure; RAAM-PEF: Randomized Aldosterone Antagonism in Heart Failure with Preserved
Ejection Fraction; Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure; TOPCAT: Treatment of Preserved Cardiac Function Heart Failure
With an Aldosterone Antagonist; EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efﬁcacy and Survival Study; RALES: Randomized
Aldactone Evaluation Study; EMPHASIS-HF: Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure.
(*) For only the patients included in ﬁnal analyses.
doi:10.1371/journal.pone.0145958.t001
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There was a significant reduction of SCD rate with AAs in patients with HF (19% SCD
reduction; RR 0.81; 95% CI, 0.67–0.98; p = 0.03) or with post-MI left ventricular dysfunction
(20% SCD reduction; RR 0.80; 95% CI, 0.66–0.98; p = 0.03). In total, the SCD rate was 4.88%
(n = 364/7451) in those treated with AAs compared with 6.08% (n = 455/7482) in those treated
with placebo/control (19% SCD reduction; RR 0.81, 95% CI, 0.71–0.92; p = 0.002) without any
evidence of statistical heterogeneity (I2 = 0%) (Fig 2A).
All-cause mortality. All-cause mortality rate in patients with HF were 16.21% (n = 729/
4496) in those treated with AAs and 19.96% (n = 903/4523) in those assigned to placebo/con-
trol (RR 0.81, 95% CI, 0.74–0.88, p<0.00001) through the follow-up duration. The correspond-
ing numbers in the sub-group of MI were 11.64% (n = 519/4460) and 13.71% (n = 611/4457),
respectively, with 15% reduction (RR 0.85; 95% CI, 0.76–0.95, p = 0.003). Altogether, there
were 1248/8956 (13.93%) and 1514/8980 (16.86%) deaths from all causes, respectively,
observed in treatment and placebo arms with a general reduction rate of 18% (RR 0.82; 95%
CI, 0.77–0.88, p<0.00001). Heterogeneity was not found in each sub-group (consisting 10 and
8 trials, respectively) and in the whole population (all I2 = 0%) (Fig 2B).
Table 2. Main criteria for patients’ eligibility in the included studies.
Studies NYHA
class
Killip
class
Creatinine (mg/dL or other
units)
Serum potassium (mmol/
L)
Ejection fraction
(%)
Boccanelli et al. 2009 (AREA-in-HF)
[35]
II NR 2.5 5.0 45
Chan et al. 2007 [56] II to III NR 200 μmol/l 5.0 <40
Cicoira et al. 2002 [22] NR NR 150 μmol/l 5.0 45
Deswal et al. 2011(RAAM-PEF) [36] II to III NR 2.5 5.0 50
Di Pasquale et al. 2005 [25] NR I to II <2.0 <5.0 NR
Edelmann et al. 2013 [32] II to III NR NR <5.1 50
Gao et al. 2007 [57] II to IV NR <2.5 <5.5 <45
Kayrak et al. 2010 [26] NR I to II 2.0 5.0 40
Mak et al. 2009 [23] IV NR 200 μmol/l NR 45
Modena et al. 2001 [27] NR I to III 2.5 NR NR
Montalescot et al. 2014 (REMINDER)
[28]
NR NR 2.5 NR 40
Pitt et al. 2014 (TOPCAT) [14] I to IV NR <2.5 5.0 45
Pitt et al. 2003 (EPHESUS) [13] I to IV NR 2.5 5.0 40
Pitt et al. 1999(RALES) [11] III to IV NR 2.5 5.0 35
Taheri et al. 2012 [37] III to IV NR NR <5.5 45
Taheri et al. 2009 [38] III to IV NR NR 5.5 45
The RALES Investigators [58] III to IV NR 2.0 <5.5 35
Udelson et al. 2010 [39] II to III NR NR 5.5 35
Uzunhasan 2009 [29] NR I to II <2.5 5.0 NR
Vatankulu et al. 2013 [30] NR I to II 2.0 <5.5 40
Vizzardi et al. 2013 [34] I to II NR NR 5.0 <40
Vizzardi et al. 2010 [59] I to II NR 2.5 5.0 40
Weir et al. 2009 [31] NR I to II 2.5 5.0 <40
Wu et al. 2013 [24] NR I to III 2.5 5.0 NR
Zannad et al. 2011 (EMPHASIS-HF)
[33]
II NR NR 5.0 35
NYHA: New York Heath Association; ND: Not Deﬁned; NR: Not Reported; 221 μmol/l ~ 2.5 mg/dL.
doi:10.1371/journal.pone.0145958.t002
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Fig 2. Efficacy of aldosterone antagonist compared with control for the prevention of (A) Sudden death, (B) All-causemortality, and (C)
Cardiovascular death in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g002
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Cardiovascular mortality. In the follow-up duration, CVmortality rate was 17.03% (n =
541/4205) in those treated with AAs and 22.54% (n = 697/4234) in those received placebo in the
HF subgroup, resulting in a reduction rate of 21% (RR 0.79; 95% CI, 0.70–0.89, p<0.00001). In
the MI subgroup, the efficacy of AAs was demonstrated by a reduction of 17% (RR 0.83; 95% CI,
0.74–0.94, p = 0.003) of CVmortality in treated patients compared with those receiving placebo
(431/4166 vs 517/4165 deaths, respectively). AAs contributed a general reduction of 20% for the
two categories of patients (RR 0.80; 95% CI, 0.74–0.87, p<0.00001) (Fig 2C).
Generally, there were likely no heterogeneity found in SCD, all-cause mortality and CV
mortality (all I2 = 0%), regarding both categories of patients.
Secondary outcomes
All-cause hospitalization. Relative risk reductions in all-cause hospitalization rate by
AAs compared with placebo/control were 9% in HF patients (RR 0.91; 95% CI, 0.86–0.96;
p = 0.0008) and 37% in post-MI patients (RR 0.63; 95% CI, 0.19–2.05; p = 0.44). In overall anal-
ysis, the results showed a significant decrease of 7% of all–cause hospitalization in patients
receiving AAs compared with those taking placebo/control (RR 0.93; 95% CI, 0.88–0.98;
p = 0.008) (Fig 3A). However, heterogeneity was likely considerable (I2 = 17%, 29% and 35%
respectively).
Cardiovascular hospitalization. In patients with HF, a significant relative risk reduction
of 21% for CV hospitalization was observed in those assigned to AAs, compared with pla-
cebo/control (RR 0.79; 95% CI, 0.68–0.91; p = 0.002). In patients with MI, the corresponding
value was 20% but not significant (RR 0.80; 95% CI, 0.47–1.35; p = 0.44). An analysis for
both subgroups showed a relative risk reduction of 18% (RR 0.82, 95% CI, 0.72–0.92;
p = 0.001) (Fig 3B). However, heterogeneity detected was moderate (I2 = 49%, 31% and 51%
respectively).
Adverse reactions
Hyperkalemia, worsening renal function and gynecomastia were the main observed side effects
of AAs in the 25 included studies, as compared to placebo or control. In general, the incidence
of all considered adverse events significantly doubled in patients treated with AAs, compared
to those receiving placebo or reference therapy. Corresponding RRs were 1.88 (Cl 95%, 1.68–
2.12, p<0.00001) for hyperkalemia; 1.45 (CI 95%,1.08–1.93, p = 0.01) for degradation of renal
function; 3.88 (CI 95%, 1.69–8.91, p = 0.001) for gynecomastia and 1.99 (95% CI, 1.64–2.41;
p<0.00001) for all considered side-effects in general, with remarkably various heterogeneities
found among the subgroups (0%, 23%, 70% and 46% respectively) (Fig 4). Exceptions appeared
for the two big RALES and EMPHASIS-HF trials [11][33], where interestingly enough, patients
in the placebo groups had slightly higher rate of gynecomastia (RALES and EMPHASIS-HF)
and of renal function degradation (EMPHASIS-HF).
Publication bias
Visual analysis of funnel plots suggested the possibility of publication biases in SCD, CV mor-
tality, total/CV hospitalization analyses, with some asymmetries (Figs 5A, 5C and 6A, 6B); this
bias was unlikely in two cases: total mortality (Fig 5B) and side effects (Fig 7).
Statistically, potential existence of publication bias was tested by Egger approach, using OR
instead of RR for the reason explained in the Method session. For clinical outcome with low
incidence (SCD, total/CV mortality, side effects), these two indicators were similar. For exam-
ple, the SCD prevention effect of AAs estimated by RR was 0.81 (95% CI, 0.71–0.92, p = 0.002)
and by OR was 0.80 (95% CI, 0.69–0.92, p = 0.002), both using random effect model. However,
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Fig 3. Efficacy of aldosterone antagonist compared to control for the prevention of (A) All-cause hospitalization and (B) Cardiovascular
hospitalization in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g003
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the higher the incidence was, the more different these estimators were. For example, for total
hospitalization criteria which had the highest incidence (over 40%), intervention effect mea-
sured by RR was 0.93 (95% CI, 0.88–0.98, p = 0.008) but by OR was 0.84 (95% CI, 0.72–0.97,
p = 0.018), both using random effect model.
Fig 4. Incidences of adverse effects (hyperkalemia, degradation of renal function and gynecomastia) under aldosterone antagonist treatment,
compared with control/placebo group, in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g004
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Most clinical outcomes in this meta-analysis included at least 10 trials, thus satisfied the rec-
ommendations on testing for funnel plot asymmetry, except the primary outcome (SCD). The
p-values of Egger tests were 0.21 for SCD, 0.79 for total mortality, 0.17 for CV mortality, 0.13
for total hospitalization, 0.08 for CV hospitalization, 0.23 for hyperkalemia, 0.94 for renal func-
tion degradation and 0.29 for gynecomastia, none supporting evidence for publication bias. Of
Fig 5. Funnel plot of standard error (log odds ratio) by odds ratio to evaluate publication bias for
effect of aldosterone antagonist treatment in preventing (A) Sudden death, (B) All-causemortality,
and (C) Cardiovascular mortality in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g005
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note, regarding both funnel plots & Egger tests, publication biases were not formally assessable
for SCD outcome due to the few number of trials included (n = 6).
Sensitivity analysis
Sensitivity analyses were tested for the biggest trial in each subgroup (among the greatest ones
REMINDER [28], TOPCAT [14], EPHESUS [13], RALES [11], EMPHASIS-HF [33]) which
had the greatest weight percentages, for eight open label/single blind/not reported design trials
if applicable (Cicoira et al. [22], Kayrak et al. [26], Mak et al. [23], Modena et al. [27],
Fig 6. Funnel plot of standard error (log odds ratio) by odds ratio to evaluate publication bias for
effect of aldosterone antagonist treatment in preventing (A) All-cause hospitalization and (B)
Cardiovascular hospitalization in patients with heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g006
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Vatankulu et al. [30], Vizzardi et al. 2013 [34], Vizzardi et al. 2010 40], Wu et al. [24]) and for
11 trials which had no intention to treat analysis (ITTA) if applicable (Boccanelli et al. [35],
Cicoira et al. [22], Deswal et al. [36], Di Pasquale et al. [25], Kayrak et al. [26], Mak et al. [23],
Taheri et al. 2012 [37], Taheri et al. 2009 [38], Udelson et al. [39], Vizzardi et al. 2013 [24],
Weir et al. [31]) (Table 1). As well, we conducted these analyses only for primary outcome, i.e
the preventive effect of AAs on mortality (SCD, total and CV death) in patients with HF or
post-MI.
Among all included trials in considering both subgroups, EPHESUS trial [13] contributed
the largest weight with relative overall weights of 44.1% for SCD, 34.6% for all-cause mortality
and 39.0% for CV mortality analyses. However, when performing a sensitivity test by excluding
this trial, no significant differences of RRs were detected for three cases: from (0.81, 95% CI
0.71–0.92, p = 0.002) to (0.81, 95% CI 0.67–0.98, p = 0.03), from (0.82, 95% CI 0.77–0.88,
p<0.00001) to (0.80, 95% CI 0.74–0.87, p<0.00001) and from (0.80, 95% CI 0.74–0.87,
p<0.00001) to (0.78, 95% CI 0.71–0.86, p<0.00001), respectively.
For patients with HF, the RALES trial [11] had the largest relative weights of 24.6%, 30.8%
and 29.4% for these three criteria, respectively. Excluding this trial resulted in no significant
difference of estimate effect for SCD analysis: RR (0.81; 95% CI, 0.67–0.98; p = 0.03) changed
to (0.82, 95% CI, 0.59–1.14) but the effective estimator turned out non-significant (p = 0.24).
The RRs for all-cause and CV mortality changed moderately from (0.81, 95% CI, 0.74–0.88,
p<0.00001) to (0.87, 95% CI, 0.77–0.98, p = 0.02) and from (0.79, 95% CI, 0.70–0.89,
p = 0.0001) to (0.83, 95% CI, 0.71–0.97, p = 0.02) respectively, with the results remained
significant.
In these patients, removing two trials which had no intention-to-treat analysis (ITTA) (Boc-
canelli et al. [35], Taheri et al. 2012 [37]) gave no remarkable influence on the AAs’ effect in
Fig 7. Funnel plot of standard error (log odds ratio) by odds ratio to evaluate publication bias for
effect of aldosterone antagonist treatment in inducing common side effects (hyperkalemia,
degradation of renal function, gynecomastia) in comparison with placebo/control, in patients with
heart failure or myocardial infarction.
doi:10.1371/journal.pone.0145958.g007
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preventing SCD: RR changed from (0.81; 95% CI, 0.67–0.98; p = 0.03) to (0.83; 95% CI, 0.69–
0.99; p = 0.04). The same attempt for three trials (Boccanelli et al. [35], Taheri et al. 2012 [37],
Taheri et al. 2009 [38]) resulted in slight changes: RR changed from (0.81, 95% CI, 0.74–0.88,
p<0.00001) to (0.81, 95% CI, 0.75–0.88, p<0.00001) and from (0.79, 95% CI, 0.70–0.89,
p = 0.0001) to (0.79, 95% CI, 0.70–0.90, p = 0.0004) in case of total/CV mortality, respectively.
Open or single blind trials in HF subgroup were also excluded for sensitivity analyses (appli-
cable for total and CV mortality analyses). Removing the three trials Cicoira et al. [22], Mak
et al. [23], Vizzardi et al. 2013 [34] for total mortality and removing the trial of Vizzardi et al.
2013 [34] for CV mortality resulted in slight changes: RR changed from (0.81, 95% CI, 0.74–
0.88, p<0.00001) to (0.81, 95% CI, 0.73–0.91, p = 0.0004) and from (0.79, 95% CI, 0.70–0.89,
p = 0.0001) to (0.83, 95% CI, 0.74–0.94, p = 0.003), respectively.
In those with MI, the EPHESUS trial [13] was the only for SCD prevention analysis. This
trial occupied the greatest relative overall weights of 34.6% and 39.0% in case of total and CV
mortality, respectively. Removing this trial returned significant changes of RRs from (0.85,
95% CI, 0.76–0.95, p = 0.003) to (0.71, 95% CI 0.48–1.05, p = 0.09) and from (0.83, 95% CI,
0.74–0.94, p = 0.003) to (0.71, 95% CI 0.43–1.18, p = 0.19), respectively.
For total mortality analysis, there was only one trial without ITTA (Weir et al. [31]) pre-
sented in the MI subgroup and removing this trial had likely no impact on RR: from (0.85, 95%
CI, 0.76–0.95, p = 0.003) to (0.85, 95% CI, 0.76–0.94, p = 0.003). Similarly, when three open
design trials (Kayrak et al. [26], Modena et al. [27], Wu et al. [24]) were removed, only slight
influences on the final effect were observed: RR changed from (0.85, 95% CI, 0.76–0.95,
p = 0.003) to (0.83, 95% CI 0.77–0.88, p = 0.006). No trial without ITTA or with single-blind/
open design involved MI patients was included for CV mortality analysis.
For SCD, all the included trials concerned HF patients with reduced LVEF, except TOPCAT
trial [14] which recruited HF patients with preserved LVEF. Removing this trial resulted in
slight change for treatment effect: RR from (0.81, 95% CI, 0.71–0.92, p = 0.002) to (0.78, 95%
CI 0.67–0.90, p = 0.0006 and the heterogeneity remained likely absent (both I2 = 0%).
Discussion
In our meta-analysis, we evaluated the efficacy of AAs in reducing mortality (SCD, overall/CV
death) and hospitalization rate, as well as their toxicity via the common side effects in 19,333
patients with HF or post-MI from 25 trials. Our findings demonstrated the effectiveness of
AAs in preventing SCD, all-cause mortality and CVmortality, yet a double rate of three studied
adverse effects in these patients.
The cardio-protective effect of AAs is quite well proven in literature for CV protection [40].
Some of the proposed mechanisms of action in HF of AAs include (i) inhibition of myocardial
and vascular remodeling, (ii) blood pressure reduction, (iii) decreased collagen deposition, (iv)
decreased myocardial stiffness, (v) prevention of hypokalemia and arrhythmia, (vi) modulation
of nitric oxide synthesis, and (vii) immunomodulation [41]. For instance, the meta-analysis of
Li et al. [42] demonstrated beneficial effects of AAs on the reversal of cardiac remodeling and
improvement of left ventricular function. Another quantified AAs’ positive effect on ejection
fraction (EF) and functional capacity improvement in different HF functional classes [43].
The RALES trial [11], published in 1999 was the first big study concerning AAs’ effect that
recommended this treatment which significantly decreased mortality rate (SCD, all cause and
CV death) as well as CV hospitalization rate in patients with severe chronic HF (NYHA III to
IV). Next, in 2003, the EPHESUS trial [13] re-confirmed the role of AAs for the same outcomes
in patients with AMI complicated by left ventricular dysfunction. This therapy was thus limited
to patients with severe HF or those with HF following MI until the publication of EMPHASIS-
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HF trial [12] in 2011, which reported additional beneficial evidence for AAs use in mild-to-
moderate HF (NYHA II), regarding the same clinical criteria. However, the current TOPCAT
trial [14] finished in 2014 showed only a significant lower incidence of cardiac hospitalization
in those treated by spironolactone vs. placebo, but not for total deaths and all-cause hospitaliza-
tion, in patients with HF and preserved EF. Sensitivity analysis with this trial suggested that the
treatment effect of AAs was likely similar in HF patients with reduced or preserved EF for SCD
prevention.
The work of Ezekowitz et al. [44] evaluated the effect of aldosterone blockade on left ven-
tricular dysfunction in HF and post-MI participants and reported a significant reduction in
overall mortality of 20% (RR 0.80, 95% CI, 0.74–0.87, p<0.00001). That of Hu et al. [45],
which showed a 21% (RR 0.79, 95% CI 0.66–0.95, p = 0.65) decrease for overall mortality and a
38% (RR 0.62, 95%, CI 0.52–0.74, p = 0.54) decrease for cardiac re-hospitalization by the use of
AAs in patients with mild to moderate chronic HF (NYHA I to II). Another current meta-anal-
ysis of Bapoje et al. [46] that included 8 RCTs, concluded a 23% reduction (OR 0.77; 95% CI,
0.66–0.89; p = 0.001) of SCD in patients with a left ventricular systolic dysfunction of 45%,
treated with AAs. On the contrary, the most recent meta-analysis of Chen et al. [47] in 2015
did not observe any all-cause mortality benefit, yet a reduced CV hospitalization rate (RR 0.83;
95% CI; 0.70 to 0.98), in patients with either HF or MI and preserved EF by AA treatment.
Our meta-analysis, included MI/ HF patients with both preserved and primarily reduced EF,
approved the positive effect of AAs in preventing all considered outcomes: SCD (RR 0.81; 95%
CI, 0.71–0.92; p = 0.002), all-cause mortality (RR 0.82; 95% CI, 0.77–0.88, p< 0.0001), CV
mortality (RR 0.80; 95% CI, 0.74–0.87, p<0.0001), all–cause hospitalization (RR 0.93; 95%
CI, 0.88–0.98; p = 0.008) and CV hospitalization (RR 0.82, 95% CI, 0.72–0.92; p = 0.001) in
patients with HF or post MI.
In terms of security, our work demonstrated a doubled rate of common adverse reactions
(hyperkalemia, worsening renal function and gynecomastia) in those receiving AAs vs. control
or placebo (RR 1.99, 95% CI, 1.64–2.41; p<0.00001). These findings agreed with the results of
currently conducted analyses by Clark et al. [48] for renal function insufficiency, or by Ros-
signol et al. [49] for hyperkalemia and renal function degradation.
In 2013, a systematic study [50] of conventional HF therapies, including angiotensin-con-
verting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), direct renin inhibitor
(DRI), and AA compared their effects (on prevention of total death, CV death, non-fatal MI,
HF hospitalization and composite of CV death or HF hospitalization) and their safety (on
hyperkalemia, hypotension, renal failure). By risk-benefit ratio comparison, this review favored
the administration of AA over ARB or DRI, despite its 110% generated increase in hyperkale-
mia. Likewise, higher proportion of developed hyperkalemia and higher rate of hospitalization
for hyperkalemia by AAs in HF patients were recorded in RALES trial, especially in combined
use of AAs with either ACEIs or ARBs [51]. Moreover, the benefit of AAs on morbi-mortality
prevention seems to overweigh its side-effects, i.e. the reduction in mortality associated with
the use of AA was significantly greater than its use complications. Our work estimated num-
bers of 83, 27 and 18 HF patients need to be treated with AAs to prevent one SCD, one all-
cause death and one CV death in one year, respectively. For patients with MI, the correspond-
ing numbers needed to treat (NNT) were 84, 48 and 48, respectively. Considering both patient
groups, the estimated NNTs were 83, 34 and 35, respectively. As well, the number needed to
harm i.e the number of patients treated on average to have one who suffers at least one of the
three common side effects studied, was 77.
Noticeably, focusing on SCD prevention, while AAs help to reduce CV risk factors thus pre-
vent CV accidents including SCD, paradoxically, their side effects of hyperkalemia may induce
this accident from cardiac arrhythmia [52]. By this point, a study [53] proved that AAs were
Aldosterone Antagonists and Sudden Death in High Risk Patients
PLOS ONE | DOI:10.1371/journal.pone.0145958 February 18, 2016 17 / 22
independently associated with increased rates of total mortality (hazard ratio HR 1.4; 95% CI
1.1–1.8; P = 0.005), of CV mortality (HR 1.4; 95% CI 1.1–1.9; P = 0.009) and a doubled inci-
dence of SCD (HR 2.0; 95% CI 1.3, 3.0; P = 0.001) in patients with atrial fibrillation and HF.
This implied a careful examination of risk/benefit ratio for each individual patient before the
prescription of this treatment.
Based on our comprehensive and meticulous search strategy, we believe that we have identi-
fied all existing studies that met our inclusion criteria, hence yielding robust results. However,
certain limitations should be considered when interpreting these outcomes. For instance, publi-
cation bias was not reliably assessed (though seemly negative) for the most important outcome
(SCD) when less than 10 studies were included for pooled analyses by funnel plot (Fig 5A) or
Egger test.
In summary, to gain the maximum benefit from AAs and reduce possible complications, it
is legitimate to individualize and closely monitor their use. For examples, risk-benefit balance
should be carefully considered before using AAs in patients with severe renal insufficiency.
Also, other factors such as time of treatment initiation [54] and cost difference between AA
agents [55] should be taken into account to optimize this therapy.
Conclusion
Our meta-analysis demonstrates that AA treatment may provide beneficial effects on the pre-
vention of SCD, as well as all-cause and CVmortality, for selected patients with HF with
altered left ventricular function or after a MI. Nevertheless, careful consideration before pre-
scribing should be given simultaneously to the therapeutic benefit and the overall safety profile
of this medication.
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